Procedure Manual Strand B: Rapid Assessments of other health technologies such as medical devices, surgical interventions or diagnostics
This document is the Procedure Manual for Rapid Relative Effectiveness Assessments of other health technologies such as medical devices, surgical interventions or diagnostics, produced by EUnetHTA JA2 WP5 Strand B. This Manual guides the production of rapid assessments of other health technologies, including process descriptions, suggested project timelines, working instructions for authors, a detailed description […]
Procedure Manual Strand A: Rapid Relative Effectiveness Assessment of Pharmaceuticals
JA2 WP5-SA Procedure Manual for Rapid REAs of pharmaceuticals
HTA Core Model for Rapid REA
JA2 WP5 – HTA Core Model for Rapid REAs
WP5 Strand A – Procedure Manual V 4
This document describes processes planned for conducting pilot rapid assessments for pharmaceuticals. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. 2012123627 – Procedure_manual_REA pilots_WP5_Strand A
The 5th pilot rapid assessment of WP5 JA2 Strand B on “Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation” is now available.
The purpose of the assessment is to address the research question whether the use of the technologies in question is more effective and/or safer than their comparators, which were chosen based on CE mark indications, recommendations in clinical guidelines for the treatment of MR and EUnetHTA guidelines. Final version of the assessment was published in […]
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment Amended JA1 Guideline Final Nov 2015
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment_Amended JA1 Guideline_Final Nov 2015
Joint Assessment on Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)
The purpose of the assessment is to evaluate Vorapaxar (ZONTIVITY™) for the reduction of cardiovascular events. Final version of the assessment was published in June 2015 Below is the documentation provided by the Joint Assessment authoring team Vorapaxar for the reduction of thrombotic cardivascular events_Rapid REA_Final_Jun 2015
Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C”
The purpose of the assessment is to evaluate multiple new pharmaceuticals for the treatment of Chronic Hepatitis C. Final version of the assessment was published in December 2015 Below is the documentation provided by the Joint Assessment authoring team: WP5-SA6 Final Appendix Feedback Complete 17122015WP5-SA6 Final Appendix Content Complete Update January 2016WP5-SA6 Final Version of […]
Endpoints used in Relative Effectiveness Assessment Surrogate Endpoints Amended JA1 Guideline Final Nov 2015
Endpoints used in Relative Effectiveness Assessment Surrogate Endpoints_Amended JA1 Guideline_Final Nov 2015
Endpoints used for Relative Effectiveness Assessment Health related quality of life and utility measures Amended JA1 Guideline Final Nov 2015
Endpoints used for Relative Effectiveness Assessment Health related quality of life and utility measures_Amended JA1 Guideline_Final Nov 2015
